HMGB1 and sRAGE: What are Their Links to Acute Myeloid Leukemia?

Authors

  • Zaridatul Aini Ibrahim Department of Pharmacology, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur
  • Kim Jun Cheng Department of Pharmacology, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur
  • Noor Atiqah Fakaruzi Department of Pharmacology, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur
  • Ariwibawa Kasmani Mohd Hashim Department of Pharmacology, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur
  • Shamsul Mohd Zain Department of Pharmacology, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur
  • Ezalia Esa Haematology Unit, Cancer Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia
  • Yuslina Mat Yusoff Haematology Unit, Cancer Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia
  • Nor Rizan Kamaluddin Haematology Unit, Cancer Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia
  • Zubaidah Zakaria Haematology Unit, Cancer Research Centre, Institute for Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia
  • Elsa Haniffah Mejia Mohamed Department of Pharmacology, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur

DOI:

https://doi.org/10.31344/ijhhs.v0i0.177

Keywords:

AML, HMGB1, sRAGE

Abstract

Introduction: Acute myeloid leukemia (AML) is a disparate hematopoietic malignancy, with many subtypes and variable responsiveness to therapy. Identification of a targetable biomarker can be used to improve survival outcome of this disease. High mobility group box 1 (HMGB1), contributes to the progression of AML by inducing various cytokines production and angiogenic vascular endothelial growth factor (VEGF). Receptor for advanced glycation end products (RAGE) exists as both a membrane and soluble receptor (sRAGE). HMGB1 is a ligand for RAGE, with sRAGE serving as a natural antagonist of RAGE signaling. Accumulating evidence suggests that HMGB1/sRAGE axis is critically involved in many cancers.

Objective: The aim of this study was to investigate whether there is a difference in the plasma levels of HMGB1/sRAGE between AML patients with good and poor prognosis and those who go into relapse.

Methods: A total of 97 plasma samples from peripheral blood were analysed for the study (47 AML, 50 healthy subjects). HMGB1 and sRAGE levels were measured using ELISA and analysed using GraphPad Prism 5.0.

Results: HMGB1 levels were found to be significantly higher in relapsed AML cases as compared to newly diagnosed cases (49.81 ± 25.25 (N=11) vs 9.461 ± 4.770 (N=36), pg/ml, p = 0.0161). HMGB1 was also significantly higher among new AML cases classified as having poor prognosis as compared to good prognosis (26.11 ± 13.31 (N=12) vs 1.135 ± 0.7147 (N=24), pg/ml, p = 0.0114). Although sRAGE levels were also high where HMBG1 levels were high, the differences were not significant.

Conclusion: HMGB1 may be used as a prognostic biomarker, as it appears to promote AML progression with higher levels seen in more malignant forms. Unravelling the mechanisms of HMGB1 in the pathogenesis of AML could provide means to regulate its expression and activities and serve as an effective treatment for more aggressive subtypes.

International Journal of Human and Health Sciences Supplementary Issue: 2019 Page: 59

Downloads

Published

2019-12-07

How to Cite

Ibrahim, Z. A., Cheng, K. J., Fakaruzi, N. A., Mohd Hashim, A. K., Mohd Zain, S., Esa, E., … Mejia Mohamed, E. H. (2019). HMGB1 and sRAGE: What are Their Links to Acute Myeloid Leukemia?. International Journal of Human and Health Sciences (IJHHS), 59. https://doi.org/10.31344/ijhhs.v0i0.177

Issue

2019: Supplementary Issue: 2019

Section

E-Poster Presentation Abstracts

License

Authors who publish in the International Journal of Human and Health Sciences agree to the following terms that:

  1. Authors retain copyright and grant International Journal of Human and Health Sciences the right of first publication of the work.

  2. Creative Commons Licence
    Articles in International Journal of Human and Health Sciences are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.

Most read articles by the same author(s)